The FDA Just Made It Way Easier to Sell a Bone-Healing Device
The FDA just reclassified non-invasive bone growth stimulators from Class III to Class II, slashing the regulatory barrier that protected incumbent players for nearly 50 years. A $2 billion market is about to get a lot more crowded.
For nearly fifty years, non-invasive bone growth stimulators have been locked behind the FDA's toughest regulatory gate. That era just ended.
On April 16, the FDA published a final order reclassifying these devices from Class III to Class II. In plain English: they went from needing the most rigorous approval process the agency has to a streamlined one. The change takes effect May 18, and it could blow open a market worth over $2 billion.
The companies that have dominated this space for decades? They fought hard to stop it.
Wait, What Even Is a Bone Growth Stimulator?
Imagine breaking your leg, getting surgery, and then the bone just… doesn't heal. It happens more often than you'd think. Non-invasive bone growth stimulators are portable devices you wear over the injury site, kind of like a high-tech heating pad for your skeleton. They send low-level energy pulses (either electromagnetic fields or ultrasound waves) through your skin to coax bone cells into doing their job faster.
Think of it like jumpstarting a car battery, except the battery is your femur.
These devices treat slow-healing fractures, failed spinal fusions, and stubborn nonunions (bones that flat-out refuse to knit back together). Typical treatment involves wearing the device for 20 to 30 minutes per session, and some protocols call for multiple sessions daily. They've shown a 92% clinical success rate as an add-on therapy for spinal fusions.
Not bad for something that looks like it belongs in a sci-fi movie from the '80s.
From Fortress to Front Door
To understand why this reclassification matters, you need to understand FDA device classes. They work like airport security tiers:
Class I: Walk right through. Basic stuff like bandages and tongue depressors.
Class II: Standard screening. You file a 510(k) notification, show your device is substantially similar to something already on the market, and you're generally good to go.
: Full-body scan, pat-down, the works. You need a Premarket Approval (PMA), which demands extensive clinical data.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Class III
Bone growth stimulators have been stuck at Class III since 1979. The FDA originally put them there because the technology was new and the risks weren't well understood. For context, that's the same year Sony introduced the Walkman.
Now, after decades of real-world data showing these devices are safe and effective, the FDA has decided that Class II with special controls is enough. The 510(k) pathway is faster and far more predictable. About 95% of 510(k) applications succeed, compared to the much more grueling PMA gauntlet.
A Long Time Coming (20 Years, Actually)
This didn't happen overnight. The push started back in 2005, when a company called RS Medical petitioned the FDA for reclassification. The following year, the FDA's Orthopaedic and Rehabilitation Devices Panel reviewed the request and said: not yet. They recommended keeping the devices at Class III, citing insufficient evidence.
The FDA agreed and shelved the idea.
Then in 2015, the agency's Center for Devices and Radiological Health took another look as part of a broader initiative to review older Class III product codes. Non-invasive bone growth stimulators (product codes LOF and LPQ, for the regulatory nerds) popped up as reclassification candidates.
By August 2020, the FDA published a proposed order to move them to Class II. The advisory panel met again in September 2020 to hash out the details. And then… silence. For over five years, the proposal sat in regulatory limbo.
Until last Wednesday.
The Special Controls: Not Exactly a Free-for-All
Before anyone panics about safety, the FDA isn't just waving these devices through. The new Class II designation comes with special controls codified under 21 CFR Part 890, designed to address seven identified risks. These include osteogenesis failure (the device not actually helping bones heal), electrical burns, electromagnetic interference, and tissue reactions.
Manufacturers will still need to provide clinical performance data, run non-clinical testing for things like mechanical durability and biocompatibility, and submit detailed software verification. They'll also need thorough labeling with usage instructions, warnings, and clinical data summaries.
One important caveat: implantable bone growth stimulators remain Class III. Only the non-invasive, external devices got the downgrade. The FDA drew a clear line between strapping something to your leg and putting something inside it.
The Incumbents Are Not Happy
If you're a company that spent millions navigating the PMA process and building a moat around your bone growth stimulator business, this news stings.
Orthofix Medical, the market leader, initially advocated for maintaining Class III status but ultimately endorsed the reclassification to Class II with special controls. CEO Jon Serbousek argued that a single set of special controls couldn't adequately cover the diverse technologies, waveforms, and designs in this device category. He wasn't alone; a coalition of bone growth stimulator manufacturers joined the opposition.
Their argument has a certain logic to it. But it also has a certain "please don't let competitors into our castle" energy. Class III designation functioned as a moat for years, keeping out smaller players who couldn't afford the PMA process. That moat just got drained.
What Happens Next
The bone growth stimulator market is valued at roughly $1.7 to $2.5 billion in 2025, depending on who's counting, with North America commanding about 41% of global share. Major players include Orthofix, Bioventus, and Zimmer Biomet.
With the regulatory barrier dropping significantly on May 18, expect a few things:
More competitors. Startups and mid-size orthopedic companies that couldn't justify the PMA expense now have a viable path to market. The 510(k) process is faster, cheaper, and far more predictable.
Price pressure. More competition generally means lower prices. That's great for patients and insurers, less great for incumbents' margins.
Incremental innovation (with a caveat). Lower barriers should accelerate product launches. But some critics worry that without PMA's rigorous clinical data requirements, manufacturers may focus on iterative tweaks rather than genuinely novel therapeutic approaches.
The FDA's move follows a broader pattern of reclassifying older Class III devices as real-world evidence accumulates. Recent examples include certain infectious disease diagnostic tests. The message is consistent: when decades of data show a device class is lower-risk than originally thought, the regulation should match the reality.
For the orthopedic industry, the castle walls just came down. The question now is who rushes through the gate first.
Funding & Financings5 min read
The Biotech Field That Didn't Exist a Decade Ago Just Got Its Biggest Bet Yet
Storm Therapeutics just raised $56 million and dosed the first patient in a Phase 2 sarcoma trial, all for a drug targeting an enzyme most people have never heard of. It's the biggest clinical milestone yet for epitranscriptomics, a therapeutic field that literally didn't exist a decade ago.
